KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Debt to Equity (2016 - 2025)

Travere Therapeutics' Debt to Equity history spans 13 years, with the latest figure at $2.1 for Q2 2025.

  • For Q2 2025, Debt to Equity changed N/A year-over-year to $2.1; the TTM value through Jun 2025 reached $2.1, changed N/A, while the annual FY2024 figure was $1.16, N/A changed from the prior year.
  • Debt to Equity reached $2.1 in Q2 2025 per TVTX's latest filing, roughly flat from $2.09 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $2.1 in Q2 2025 to a low of -$2.25 in Q3 2024.
  • Average Debt to Equity over 5 years is $0.32, with a median of $0.06 recorded in 2023.
  • Peak YoY movement for Debt to Equity: tumbled 70.27% in 2021, then skyrocketed 566.92% in 2022.
  • A 5-year view of Debt to Equity shows it stood at $0.02 in 2021, then soared by 566.92% to $0.16 in 2022, then crashed by 63.74% to $0.06 in 2023, then soared by 1862.55% to $1.16 in 2024, then skyrocketed by 80.82% to $2.1 in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Debt to Equity are $2.1 (Q2 2025), $2.09 (Q1 2025), and $1.16 (Q4 2024).